An observational study in Genital Herpes and Patient Engagement, sponsored by Rational Vaccines Inc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-01-18.
Sponsored by Rational Vaccines Inc · Observational
Determine the baseline characteristics of patients who have recurrent symptomatic genital herpetic disease Determine the acceptance to patients of clinical trial procedures Determine interest in participation in genital herpes vaccine trials
70 studies on the registry are indexed under Herpes Genitalis; 3 are open to participants now.
This study's enrollment of 68 is below the median of 300 across 14 observational studies indexed under Herpes Genitalis.
Browse Herpes Genitalis studies →This is the only study on the registry with Rational Vaccines Inc as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients with recurrent symptomatic of genital herpes
Exclusion Criteria:
Baseline characteristics of patients who have recurrent symptomatic genital herpetic disease
To determine using a questionnaire * number of annual outbreaks of patients who have recurrent symptomatic genital herpetic disease * number of patients using suppressiv antiviral therapy * number of patients using antivirals for the treatment of outbreaks * number of patients using symptomatic therapy other than antivirals
Time frame: day of questionnaire
Acceptance to patients of clinical trial procedures
To determine using a questionnaire - the acceptance to patients of clinical trial procedures
Time frame: day of questionnaire
Interest in participation in genital herpes vaccine trials
To determine using a questionnaire the number of patients interested in participation in genital herpes vaccine trials
Time frame: day of questionnaire
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.